Study Summaries

Study summaries are free for everyone to read. Requires registration for free account of GYOEDU

Cervical Cancer

• Early Disease

  • SHAPE Trial: Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer

• Locally Advanced Disease

  • EORTC-55994: Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
  • OUTBACK Trial: Chemotherapy after Chemoradiation
  • KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
  • CALLA: Durvalumab versus placebo with chemoradiotherapy

• Recurrent/Metastatic Disease

  • BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
  • KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Endometrial Cancer

• Surgical Trials

  • GOG 33: Surgical Pathologic Spread Patterns of Endometrial Cancer
  • GOG-LAP2: Laparoscopy Compared With Laparotomy for Endometrial Cancer Staging
  • LACE trial: Laparoscopy vs. Open for Endometrial Cancer
  • Sentinel Lymph Nodes
    • Fires Trial: Sentinel LND in Endometrial Cancer
    • Sentor Trial: Sentinel LND in High-Grade Endometrial Cancer

• High-Risk

  • GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
  • PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk

• Advanced/Recurrent Disease

  • GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer
  • GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
  • PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer
  • GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
  • NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
  • Immunotherapy Trials
    • Upfront therapy
      • NRG GY018: Pembrolizumab in Advanced Endometrial Cancer
      • RUBY - Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
      • DUO-E trial: Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib
    • Recurrence
      • KEYNOTE 775: Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Ovarian Cancer

• Surgical trials
  • SCORPION: Primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer
  • DESKTOP Trial - Secondary Debulking Surgery
• Upfront therapy
  • OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
  • MITO-7: Weekly chemotherapy in ovarian cancer
  • GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
  • ICON 8: Weekly dose-dense chemotherapy in first-line epithelial ovarian
• Maintenance Trials
  • PRIMA: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
  • PAOLA-1: Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
• Platinum-Sensitive Disease
  • CALYPSO trial: Carboplatin+ Doxil vs. Carboplatin+Taxol
• Platinum-Resistant Disease
  • MIRASOL: Mirvetuximab in Platinum Resistant Cancer
• Low-Grade Ovarian
  • GOG 281: Trametinib in recurrent low-grade serous ovarian cancer

Vulvar Cancer

• Locally Advanced Disease
  • GOG 279: Cisplatin, Gemcitabine, and IMRT for Locally Advanced Vulvar Carcinoma

Sarcoma

• GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
• GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas
• LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

Old Study Summaries

To access old study summaries submitted by volunteers, click here:

Study Summaries as an Airtable (full window)